A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor Alpha (FolRa) Antibody-Drug Conjugate (ADC) in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor Alpha (FolRa) Antibody-Drug Conjugate (ADC) in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Ovarian & Endometrial Cancers
Age: Between 18 years - 100 years
Gender: Female

Other Inclusion Criteria:

1) ECOG performance status (0-1). 2) Life expectancy > 3 months. 3) Adequate bone marrow, liver and renal functions. 4) Recurrent ovarian or endometrial cancer.

You may not be eligible for this study if the following are true:

1) Low grade ovarian carcinoma (Grade 1). 2) Clear cell, mucinous and sarcomatous ovarian carcinomas. 3) Prior treatment with a FolRa-targeting ADCs or FolRa-targeting vaccines. 4) Subjects who are platinum-refractory.